Immune checkpoint blockade withPD-1/programmed cell death ligand 1 (PD-L1) inhibitors has thus become part of thestandard-of-care treatment option for patients with advanced stage NSCLC; however,only a small subset (20–30%) of patients respond to treatment.16, , , , , , , , –25. Here, CD274 is linked to non-small cell lung carcinoma.